Proteostasis Therapeutics, the Cambridge, MA-based company seeking to keep proteins in balance to fight neurodegenerative diseases, said today it has obtained two exclusive technology licenses from Harvard University. The licenses pertain to the ubiquitin-proteosome pathway, and include biological targets and small-molecule drug candidates. Proteostasis, founded by Healthcare Ventures in Boston with technology from The Scripps Research Institute in San Diego, isn’t disclosing financial terms of the deal. The new batch of intellectual property comes from the Harvard labs of Daniel Finley, Randall King, and Alfred Goldberg, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
